AnaptysBio, Inc. (LON:0HFQ)

AnaptysBio Statistics

Total Valuation

AnaptysBio has a market cap or net worth of GBP 397.99 million. The enterprise value is 457.15 million.

Market Cap	397.99M
Enterprise Value	457.15M

Important Dates

The next estimated earnings date is Friday, October 31, 2025.

Earnings Date	Oct 31, 2025
Ex-Dividend Date	n/a

Share Statistics

Current Share Class	28.00M
Shares Outstanding	n/a
Shares Change (YoY)	+10.75%
Shares Change (QoQ)	-5.98%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	15.98M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	4.43
PB Ratio	-12.19
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Enterprise Valuation

EV / Earnings	-4.72
EV / Sales	5.07
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	-4.89

Financial Position

The company has a current ratio of 8.22

Current Ratio	8.22
Quick Ratio	8.08
Debt / Equity	n/a
Debt / EBITDA	n/a
Debt / FCF	-2.71
Interest Coverage	-1.22

Financial Efficiency

Return on Equity (ROE)	n/a
Return on Assets (ROA)	-14.12%
Return on Invested Capital (ROIC)	-15.59%
Return on Capital Employed (ROCE)	-28.74%
Revenue Per Employee	661,010
Profits Per Employee	-711,620
Employee Count	136
Asset Turnover	0.32
Inventory Turnover	n/a

Taxes

In the past 12 months, AnaptysBio has paid 56,202 in taxes.

Income Tax	56,202
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -42.26% in the last 52 weeks.

Beta (5Y)	n/a
52-Week Price Change	-42.26%
50-Day Moving Average	23.20
200-Day Moving Average	19.91
Relative Strength Index (RSI)	38.92
Average Volume (20 Days)	279

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	19.31

Income Statement

In the last 12 months, AnaptysBio had revenue of GBP 89.90 million and -96.78 million in losses. Loss per share was -3.26.

Revenue	89.90M
Gross Profit	-29.66M
Operating Income	-62.87M
Pretax Income	-96.72M
Net Income	-96.78M
EBITDA	-62.45M
EBIT	-62.87M
Loss Per Share	-3.26

Balance Sheet

The company has 193.94 million in cash and 252.88 million in debt, giving a net cash position of -58.94 million.

Cash & Cash Equivalents	193.94M
Total Debt	252.88M
Net Cash	-58.94M
Net Cash Per Share	n/a
Equity (Book Value)	-32.65M
Book Value Per Share	-1.17
Working Capital	187.13M

Cash Flow

In the last 12 months, operating cash flow was -93.21 million and capital expenditures -271,523, giving a free cash flow of -93.48 million.

Operating Cash Flow	-93.21M
Capital Expenditures	-271,523
Free Cash Flow	-93.48M
FCF Per Share	n/a

Margins

Gross margin is -33.00%, with operating and profit margins of -69.94% and -107.66%.

Gross Margin	-33.00%
Operating Margin	-69.94%
Pretax Margin	-107.59%
Profit Margin	-107.66%
EBITDA Margin	-69.47%
EBIT Margin	-69.94%
FCF Margin	n/a

Dividends & Yields

AnaptysBio does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-10.75%
Shareholder Yield	-10.75%
Earnings Yield	-24.32%
FCF Yield	-23.49%

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

AnaptysBio has an Altman Z-Score of -1.93 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	-1.93
Piotroski F-Score	4